Roger A. Jeffs, Ph.D., has led Liquidia Corporation as its CEO since January 2022. With a strong background in pharmacology, he holds a Ph.D. from the University of North Carolina and a Bachelor's in Chemistry from Duke University. Before joining...
Roger A. Jeffs, Ph.D., has led Liquidia Corporation as its CEO since January 2022. With a strong background in pharmacology, he holds a Ph.D. from the University of North Carolina and a Bachelor's in Chemistry from Duke University. Before joining Liquidia, he served for 18 years at United Therapeutics Corporation, where he was a key player in their early growth, overseeing the development of important products for rare diseases. His experience includes positions at Amgen and Burroughs Wellcome, showing a solid foundation in both research and business. In 2023, Dr. Jeffs earned a total compensation of approximately $431,000, which reflects a significant cash bonus related to the company meeting its performance goals. He is also known for his substantial stock holdings, positioning himself as a significant stakeholder in Liquidia's future. Under his leadership, Liquidia is navigating its path toward a more commercial presence in the biotechnology sector, focusing on innovative treatments.